ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) approval of its first radiofrequency (RF) wireless devices to treat patients with heart failure and with potentially lethal heart arrhythmias. The Promote™ RF CRT-D (cardiac resynchronization therapy defibrillator) and Current™ RF ICD (implantable cardioverter defibrillator) feature radiofrequency telemetry for wandless communication with programmers used by physicians to interrogate and program devices.
